Jim Cramer on ImmunityBio: “I Really Think That You Have to Take Profits in Some of That”

Okay, present that… spot what happens, I deliberation is you already had that. That moved gigantically. It’s had a elephantine tally disconnected this FDA meeting, and I truly deliberation that you person to instrumentality profits successful immoderate of that, not each of it, but immoderate of it, due to the fact that it’s up truthful big.

Photo by Artem Podrez connected Pexels

ImmunityBio, Inc. (NASDAQ:IBRX) develops therapies designed to fortify the immune strategy against infectious diseases and respective cancers. During the May 19, 2025, episode, Cramer was asked astir the banal by a caller, and helium replied:

IBRX is not a large stock, ImmunityBio. I’ve looked astatine it for a very, precise agelong time. I don’t similar the information that they are, they’ve been losing wealth forever. I americium not successful their camp.

It is important to enactment that since the supra remark was aired, the company’s banal has gained implicit 130%. Furthermore, the banal is up implicit 220% year-to-date.

While we admit the imaginable of IBRX arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the champion short-term AI stock.

READ NEXT: 30 Stocks That Should Double successful 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This nonfiction is primitively published astatine Insider Monkey.